Search

The article presents a proof of concept for an endpoint staging framework applied to the Alzheimer Management by Albumin Replacement (AMBAR) study. This framework aligns clinical trial endpoints (such as cognitive, functional, and quality-of-life measures) to specific Alzheimer’s disease (AD) stages where these outcomes are most relevant. The goal is to improve the sensitivity of clinical trial results by targeting endpoints to the disease stage where they are most likely to show significant changes. Findings suggest that applying this framework increases the observed treatment efficacy for targeted stages, supporting the idea that staging-specific endpoints can yield more accurate assessments of therapeutic benefits in AD trials.